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Introduction
The literature describing antibiotic prescribing patterns to treat
urinary tract infections in skilled nursing facilities in Hawaii is
limited. Antibiotics are primarily used in skilled nursing facilities
to treat urinary tract infections, respiratory infections, skin or soft
tissue infections, and gastroenteritis. It is generally believed that
organisms isolated in a skilled nursing setting are more resistant.
However, this may not be true for some of our facilities in Hawaii.
In the community, as well as in the acute care situation, physicians
routinely draw urine cultures to determine antibiotic sensitivities.
They may need to treat empirically depending on the clinical
situation or according to C&S results, Despite the information
provided by C&S reports that document the sensitivity of the
causative organism to older, less expensive antibiotics, such as
amoxicillin. trimethoprim/sulfamethoxazole, ornitrofurantoin, many
physicians still opt to use more expensive, broad spectrum antibiot
ics, such as quinolones, to treat urinary tract infections.3 This
practice may have serious long term implications to an institution in
terms of escalating healthcare costs and developing resistant organ
i sms.
Background
An Antibiotic Ad-Hoc Committee was convened at a I 58-bed
skilled nursing facility in Honolulu, Hawaii to focus on the follow
ing issues:
I. To identify the “perceived” problems with antibiotic utilization in
our facility
2. To prioritize issues that need to he addressed
3. To design a study plan that defines and quantifies the problem
with a time line for each issue to he studied
4. To develop possible strategies to correct any problem identified
with antibiotic utilization
The committee initially wanted to characterize the prevalent
antibiotic usage patterns of our physicians in the treatment of urinary
tract infections. The committee wanted to know what were the most
common antibiotics used empirically to treat UTI’s. The committee
also wanted to know what antibiotics physicians tended to choose
when C&S results were available, In other words, did they choose
older, less expensive antibiotics when C&S data demonstrated
sensitivity or did they choose newer, more broad spectrum. and
more expensive antibiotics’? If treatment was begun empirically
with a newer, more expensive antibiotic, was therapy switched to an
older, less expensive antibiotic upon receipt of C&S data that
demonstrated organism sensitivity? If not, what would he the cost
and clinical implications to our facility with the “overuse” of newer.
and more expensive antibiotics’?
Methodology
In order to answer these questions, aquestionnaire was developed by
the antibiotic committee (See Appendix 1) and approved by the
Pharmacy and Therapeutics Committee. The clinical pharmacist
and infection control nurse conducted a retrospective chart review
on all available UTI data from July 2001 to February 2002. Unfor
tunately, only seventeen charts with the required data were available
for review, and of these, only fourteen were evaluable.
All patients without catheters had documented UTI’s as defined
by at least three of the following criteria: fever> I 00 degrees
Fahrenheit or chills, burning pain on urination, frequency or ur
gency, flank or suprapubic pain or tenderness, change in the charac
ter of the urine, worsening of mental or functional status, urine
culture with >100,000 colonies per ml of single uropathogen in
patient on appropriate antibiotic therapy. For patients with cath
eters, documented UTI’s were defined by at least two of the above
criteria, with the exception of “burning pain on urination.”
All antibiotic sensitivities were evaluated for each organism.
Sensitivity results were compared with actual treatment choices. A
daily’ antibiotic cost comparison chart was developed to calculate the
total costs of antibiotic therapy. These costs were then compared
with the overall cost of a less expensive alternative, such as
amoxic illin, which had the lowest daily cost, followed by
trimethoprim/sulfamethoxazole.
Although documentation in most cases was rather scanty. the
study also tried to see if any of these patients experienced any UTI’s
in the past 30 days to determine if the present UTI was a result of
reinfection or a resistant organism. The thought was that therapeutic
choice might very well have been influenced by a patient’s predis
position to recurrent UTI’s.
The Antibiotic Ad-Hoc Committee originally planned to review
at least thirty charts, hut due to lack of adequate patient information,
we were only able to review fourteen charts, Despite the limit of this
study, certain trends became readily apparent . .Since no study of this
kind had ever been conducted at our facility (or any other skilled
nursing facility in Hawaii to the best of our knowledge, the
committee thought it beneficial to share the results of the study with
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the medical staff. The committee anted to see if there was an
indirect evidence to support the generall held view that antibiotic
resistance is pie\ alentand, therefore. empiric iherap withqumolones
s tustitied at our facility.
Results
Of the ses enteen c harts as ailable for tes ies onE louileen
ssere es aluable. Females crnpriscd (— percent of the siud - on
average. crc 0 years older and received, on averae. 2.6 fewerdavs
of antibiotic therap (Table I
Qtiinolones cipr tloxacinorlcuollo\acin serethe rrcdonnnant
drugs used to treat [Ti’s 57’ i. (1 able II In ses en of these eieht
cases XS . based on C&S results. ainoxicillin or trimethoprtm/
sulfamethoxazole, could have been used in lieu ofquinolones. C&S
tests were ordered before commencing treatment in a vast majorit\
of cases (93ff).
Empiric therapy began before receipt of C&S results in five of
fourteen cases (36%). In fourof these five cases (80%). C&S results
showed that the causative organisms were sensitive to either
amoxicillin or trimethoprim/sulfamethoxatole. (Table Ill)
Treatment started after receipt of C&S results in nine of fourteen
C ises (64 ) In dl of these eases l00 ) C cc,S tesults showed that
the causative organisms were sensitive to either amoxicillin or
trimethoprnn/sulfamethoxazole. In no instance ss as therapy switched
upon receipt of C&S data documenting organism sensitivit\ to a less
expensis e antibiotic.
Overall. 93 percentofC&S results shos ed sensitivity toamoxicillin
or trnnethopi-im! sulfamethoxazoic. In 43 percent of cases. [TI’s
were treated with less expensive, more narrow spectrum antibiotics.
while in 57 percent of cases. [TI’s were treated with a quinolone.
a more expensive alternative. ( Fable IV If all non—penicillin
allergic patients had been started on amoxicillin. the potential
savings to the facility would have been 5142.37. ss hich translates to
about SI 092.0() for every 100 [TI’s treated.
None of the patients experienced any Lii’s 30 days prior to their
most recent [TI. There was noes idence of reinfection or that any
of the present [TI’s were caused h resistant organisms.
Conclusion
AlthoLigh data was limited, our study showed that in fewer than half
the cases evaluated, physicians chose less expensive, more narrow
spectrnni antibiotics to treat [Ti’s. Quinolones. which are expen
sive, broad spectrum antibiotics, were the predominant drugs used
to treat [TI’s when less expensive, more narross spectrum antihiot
mc could has e been chosen. The data in this study needs to he
reconfirnied at other tacdities and s imb lareer sample sizes Hoss -
es er. the rends noted in antibiotic usage at this facility make an
inmerestme tarnne point to teexamine the validit oF current pie-
scribing practices in Hassan based on local sensitis it data. The
us eruse of broad spectrum antibb tics ocr a proluneed period of
i me has been associated svi t h the devc I Tmlleni of tesi tant oran -
siLls and this has serious implications to the health and well-being
of an institution’s resi-dcnts. Theic ai’e alsu potential cost savings to
an institution o hen non—quinolone antibiotics are appropriatcl
used totreai nrjnar\ tract infections. In an era of financial constraints
and erosvnmv problems with amibiotic resistance, it is imperative that
healtlicare professionals reexamitmc’ the tuindset that predisposes
clinicians to utilize very powerful, last-line drugs. as a first choice.
when older, less expensive alternatives ma he equally appropriate.
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Table 2,— Drugs Used to Treat UTVs
DRUGS NUMBER Cu
Cprotloxacrn
— 50%
Levctloxaen
Nlrofuratoin 2 1 50;
Amoactln 2 ‘45.
TMP SMX
Pen’cl/n VK ‘ 7%
Table 1
.— Demographics
Table 4—Relative Daily Cost Index of Antibiotic Regimins Used to
Treat UTIs Amoxmcillin = 1.0 least expensive regimen I
FEGUEt) 7QST
CC EF 09
Amoxiciltin 25OmgPOTID 1.0
TMP..SMX)Bactrim DS( I 051% 30 BlD 23
Nitroturantain (Macrobid) iOOmo Pt) Bit) 50
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Appendix One
Drug Utilization Review Criteria
Patient Name: —__________________________________ Medical Record So:
Sex:
________
Age:
________
Physician:
________________—____________
Drug Allergies: —
1. C&S ordered for suspected UTI? — Yes — No
2. Cultures taken before antibiotic Matted? Yes No
3. Date C&S results recehed at Maluhia?
_
Date reported to MD:
___
___
___
__
4. Antibiotic prescribed:
______ __-. ___
___ ____ ___ __
5. Date started:
___________
Duration of Therapy:
______ ___
6. Last UTI for this patient:
__ __ __ __
7. C&S Results:
At Organism:
B. Sensitive to:
C. Resistant to:
8. Iforganism was sensitive to less expensive antibiotic, was therapy switched? — Yes — No
10. Any documentation explaining why therapy was not switched? — Yes — No
11. Potential Cost Savings in Switching ofAntibiotic Therapy:
A. Cost/day of therapy = x
days
=
B. (‘ostday of alternate therapy: -
Number of Days Left in Switch:
_ _
Total Coat
C. Cost/day oforiginal therapy:
Number ofdays received:
_
Total Cost:
D. TotalcostB_C=
E. POTENTIAL COST SAVINGS (A - D) —_____
12. Potential Cost Savings if Therapy Started Empirically with Less Expensive Antibiotic:
A. Cost/dayof therapy:
x
__days=
B. Coat/day alt. therapy: days =
C. POTENTIAL COST SAVINC;S (A-B)
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POISON CENTER TIPS
• Keep the number of the Hawaii Poison Center on
or near your telephone.
• if you suspect a poisoning, do !2 wait for signs
and symptoms to develop. Call the Hawaii Poison
Center immediately.
• Always keep Ipecac Syrup in your home. (This is
used to make a person vomit in certain types of
poisoning.) Do not use Ipecac Syrup
unless advised by the Hawaii Poison
Center.
• Store all medicines, chemicals, and household
products out 0f reach and out 0f sight, preferably
locked up.
• A good rule to teach children is to “always ask
first” before eating or drinking anything—don’t
touch, don’t smell, don’t taste.
Donate to help us save lives.
Mcii checks, payable to:
Hawaii Poison Center
1319 Pnabcu Street. HonoIuIu HI 96826
OAHU: 941-4411
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